drugset / Trial / NCT02784067

A Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency

NCT02784067 ↗

Phase 4 Withdrawn QOL Medical, LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

S09A is a Phase 4, multicenter, randomized, double-blind, placebo-controlled, parallel study examining the efficacy and safety of a Sucraid (sacrosidase) Oral Solution in comparison to a placebo in 150-200 subjects with chronic diarrhea possibly attributable to sucrase deficiency.

Timeline

Start
2016-05
Primary completion
2017-12
Completion
2017-12

Outcome

Outcome not reported

Stopped: “Clinical Trial Material”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sacrosidase Protein / enzyme biologic 2 ml Oral
Subject Sacrosidase Protein / enzyme biologic 17000 iu Oral